A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 160 participants.

Also called NCT07360275

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Vincentage Pharma Co., Ltd (from the registry)
Registry
  • NCT NCT07360275
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07360275. Randomized; double masking; primary purpose treatment. Start 2026-03-01 (actual); primary completion 2026-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
Acronym
VICTOR-HTN
Condition
Hypertension
Intervention (Drug)
VCT220 Tablet
Intervention (Drug)
VCT220 Placebo Tablet
Lead sponsor
Vincentage Pharma Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07360275
Content hash
f3257b598343bf404b1b6888c50ae13d0aae5116cb68a279a0cd61c24cd9806c